CompletedPhase 3NCT05255237

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Principal Investigator
Jianzhong Zhang, PhD
Peking University People's Hospital
Intervention
Jaktinib(drug)
Enrollment
315 enrolled
Eligibility
18-65 years · All sexes
Timeline
20222024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05255237 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials